MiNK Therapeutics Inc INKT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
-
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
-
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
-
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
-
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
Trading Information
- Previous Close Price
- $9.94
- Day Range
- $9.38–10.10
- 52-Week Range
- $8.48–16.93
- Bid/Ask
- $8.00 / $10.15
- Shares Outstanding
- 5.10M
- Market Cap
- $48.02M
- Volume/Avg
- 13,626 / 13,766
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 15
- Website
- https://www.minktherapeutics.com
Valuation
|
Metric
|
INKT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
INKT
|
|---|---|
Quick Ratio | 1.16 |
Current Ratio | 1.23 |
Interest Coverage | — |
Quick Ratio
INKT
Profitability
|
Metric
|
INKT
|
|---|---|
Return on Assets (Normalized) | −91.87% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
INKT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|g^bzSL | LOCK|Z!!qt | $127B | |||
| Moderna Inc
MRNA
| LOCK|&&@@pD& | LOCK|>YG | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Zv@&mg$ | LOCK|V##^$ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|&cmTC& | LOCK|^@ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&<f??h& | LOCK|%># | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|n??DGDQ | LOCK|!p^V | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Kt>%#fS< | LOCK|&BwWX | $27B | |||
| Incyte Corp
INCY
| LOCK|Q>XF#M | LOCK|<F | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|K?<KN> | LOCK|@? | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|mnh@<J& | LOCK|Bs? | $14B |
United States